Stroke Prevention in Atrial Fibrillation – The Use of NOACs in Everyday Clinical Practice

Journal
Article on Stroke Prevention in Atrial Fibrillation – The Use of NOACs in Everyday Clinical Practice

Add this Moment to your Passport

Learn from this moment and keep it forever.
FREE
Add To Passport

Overview

Non-antivitamin K oral anticoagulants (NOACs) have recently emerged as a new class of antithrombotic drugs. Four large-scale, randomised controlled trials (RCT) accredited dabigatran, rivaroxaban and edoxaban with evident advantages for stroke prevention in atrial fibrillation (AF) compared with warfarin. The superiority concerns not only the manageability but also the antithrombotic efficacy and safety. Aspects of real-life clinical experience with NOAC for stroke prevention in AF are analysed in an attempt to underline some practical differences. If at present the individualisation of the NOAC class drugs is still a subject of debate it is probable that in the near future we will be able to adapt the drug and dosages to individual patient’s profile.

Featuring

Gheorghe-Andrei Dan -  Organization: International Society of Cardiovascular Pharmacotherapy

Adrian Catalin Buzea -  Organization: University of Medicine ‘Carol Davila’ – Colentina University Hospital, Bucharest, Romania

Loading Simple Education